JP2012082227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012082227A5 JP2012082227A5 JP2012014178A JP2012014178A JP2012082227A5 JP 2012082227 A5 JP2012082227 A5 JP 2012082227A5 JP 2012014178 A JP2012014178 A JP 2012014178A JP 2012014178 A JP2012014178 A JP 2012014178A JP 2012082227 A5 JP2012082227 A5 JP 2012082227A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- neoplastic agent
- agent
- protective
- neoplastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 19
- 230000001681 protective effect Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 5
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- HQVAVYYAPZDXHV-UHFFFAOYSA-N 2-nitro-1h-imidazole;hydrobromide Chemical compound Br.[O-][N+](=O)C1=NC=CN1 HQVAVYYAPZDXHV-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45884503P | 2003-03-28 | 2003-03-28 | |
| US60/458,845 | 2003-03-28 | ||
| US46528103P | 2003-04-21 | 2003-04-21 | |
| US60/465,281 | 2003-04-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509466A Division JP2006521409A (ja) | 2003-03-28 | 2004-03-29 | 癌を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012082227A JP2012082227A (ja) | 2012-04-26 |
| JP2012082227A5 true JP2012082227A5 (https=) | 2013-03-07 |
| JP5572644B2 JP5572644B2 (ja) | 2014-08-13 |
Family
ID=33135116
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509466A Ceased JP2006521409A (ja) | 2003-03-28 | 2004-03-29 | 癌を処置するための組成物および方法 |
| JP2012014178A Expired - Fee Related JP5572644B2 (ja) | 2003-03-28 | 2012-01-26 | 癌を処置するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509466A Ceased JP2006521409A (ja) | 2003-03-28 | 2004-03-29 | 癌を処置するための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7550496B2 (https=) |
| EP (2) | EP2671581B8 (https=) |
| JP (2) | JP2006521409A (https=) |
| KR (2) | KR101198526B1 (https=) |
| CN (2) | CN1791403A (https=) |
| AU (1) | AU2004226338C1 (https=) |
| CA (1) | CA2520000C (https=) |
| ES (1) | ES2759176T3 (https=) |
| IL (1) | IL170970A (https=) |
| MX (1) | MXPA05010407A (https=) |
| NO (1) | NO336266B1 (https=) |
| NZ (1) | NZ543223A (https=) |
| WO (1) | WO2004087075A2 (https=) |
| ZA (1) | ZA200507752B (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| US7691838B2 (en) | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
| DE50305909D1 (de) * | 2003-10-13 | 2007-01-18 | Salama Zoser B | Pharmazeutische Zusammensetzung umfassend Oxoplatin und dessen Salze |
| WO2005086951A2 (en) * | 2004-03-10 | 2005-09-22 | Threshold Pharmaceuticals, Inc. | Hypoxia-activated anti-cancer agents |
| GB0421296D0 (en) * | 2004-09-24 | 2004-10-27 | Angiogene Pharm Ltd | Bioreductively-activated prodrugs |
| US7208611B2 (en) | 2005-02-23 | 2007-04-24 | Xenoport, Inc. | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use |
| JP2006282653A (ja) * | 2005-03-10 | 2006-10-19 | Kyoto Univ | 標的部位で選択的に活性化される新規化合物およびその利用 |
| CN102746336B (zh) * | 2005-06-29 | 2015-08-19 | 施瑞修德制药公司 | 氨基磷酸酯烷化剂前体药物 |
| EP2114157B1 (en) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
| EP2136626A4 (en) | 2007-03-19 | 2011-02-23 | Oregon State | Mannich base n-oxide drugs |
| WO2008151253A1 (en) * | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| WO2009018163A1 (en) * | 2007-07-27 | 2009-02-05 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of anthracyclines |
| WO2009033165A1 (en) * | 2007-09-06 | 2009-03-12 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of bis-alkylating agents |
| US20090118031A1 (en) * | 2007-11-01 | 2009-05-07 | Qualizza Gregory K | Shaft Structure with Configurable Bending Profile |
| JP5765634B2 (ja) | 2008-10-21 | 2015-08-19 | スレッシュホールド ファーマシューティカルズ， インコーポレイテッド | 低酸素活性化型プロドラッグを用いるがんの処置 |
| WO2010073126A2 (en) * | 2008-12-22 | 2010-07-01 | The Governors Of The University Of Alberta | Compounds useful in delivering anti-neoplastic therapy and diagnostic imaging to hypoxic cells and methods of use thereof |
| CN101538256B (zh) * | 2009-04-28 | 2014-05-21 | 沈阳药科大学 | 3，4-二芳基呋喃-2，5-二酮类衍生物与3，4-二芳基-1h-吡咯-2，5-二酮类衍生物及其用途 |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| WO2012009288A2 (en) | 2010-07-12 | 2012-01-19 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| CA2820245A1 (en) * | 2010-12-06 | 2012-06-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents |
| US9402820B2 (en) | 2011-04-22 | 2016-08-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors |
| CN102260273B (zh) * | 2011-05-13 | 2015-04-22 | 兰州大学 | 脱氧鬼臼与5-氟尿嘧啶的拼合物及其制备与用途 |
| WO2013096687A1 (en) | 2011-12-22 | 2013-06-27 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer |
| HK1203412A1 (en) | 2011-12-28 | 2015-10-30 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| ES2643403T3 (es) | 2011-12-28 | 2017-11-22 | Global Blood Therapeutics, Inc. | Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
| BR112014017833A2 (pt) | 2012-01-20 | 2021-03-23 | Dennis Brown | Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma |
| US9655975B2 (en) | 2012-02-13 | 2017-05-23 | University Of Tsukuba | Prodrug using nitroimidazole |
| CN104204035B (zh) | 2012-03-30 | 2017-05-24 | 宇部兴产株式会社 | 具有封端基团的聚轮烷的制造方法 |
| WO2014058974A1 (en) * | 2012-10-10 | 2014-04-17 | Emory University | Methods of managing inflammation using glycolysis pathway inhibitors |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US10037382B2 (en) | 2012-10-29 | 2018-07-31 | Kyocera Corporation | Surface acoustic wave sensor |
| CN107412163A (zh) | 2012-12-03 | 2017-12-01 | 梅里马克制药公司 | 用于治疗her2‑阳性癌症的组合疗法 |
| EP2777694A1 (en) | 2013-03-14 | 2014-09-17 | Brij P. Giri | Hypoxia-Targeted Polymeric Micelles for Cancer Therapy and Imaging |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2014150261A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulaton of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2014150258A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| MX379235B (es) | 2013-03-15 | 2025-03-11 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| WO2014181314A1 (en) | 2013-05-10 | 2014-11-13 | Department Of Biotechnology | Placental like alkaline phosphatase (plap) promoter mediated cell targeting |
| US20160158253A1 (en) | 2013-07-26 | 2016-06-09 | Threshold Pharmaceuticals, Inc. | Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| CN104434876B (zh) * | 2013-09-13 | 2018-04-27 | 布里吉·P·吉里 | 用于癌症疗法及成像的缺氧-标靶聚合微胞 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| WO2016011195A1 (en) | 2014-07-17 | 2016-01-21 | Threshold Pharmaceuticals, Inc. | Th-302 solid forms and methods related thereto |
| BR112017019287B1 (pt) | 2015-03-10 | 2024-01-02 | Obi Pharma, Inc | Composto, e composição farmaceuticamente aceitável |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| US10829437B2 (en) | 2015-04-02 | 2020-11-10 | Obi Pharma, Inc. | Nitrobenzyl derivatives of anti-cancer agents |
| WO2016210175A1 (en) | 2015-06-24 | 2016-12-29 | Threshold Pharmaceuticals, Inc. | Aziridine containing dna alkylating agents |
| CA2998483C (en) | 2015-09-16 | 2022-09-06 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
| CN105250325A (zh) * | 2015-10-28 | 2016-01-20 | 淄博齐鼎立专利信息咨询有限公司 | Demissine在制备治疗肾癌药物中的应用 |
| SG11201804647TA (en) | 2015-12-04 | 2018-06-28 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| CN106554375B (zh) * | 2016-06-08 | 2019-10-18 | 浙江海正药业股份有限公司 | 一种蒽环类化合物、其制备方法及其用途 |
| US20210369746A1 (en) | 2016-08-01 | 2021-12-02 | Molecular Templates, Inc. | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| WO2018170196A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
| CN106977501A (zh) * | 2017-03-20 | 2017-07-25 | 华东师范大学 | 一种基于2‑硝基咪唑‑1‑烷基醇的低氧激活前药 |
| CN107417672A (zh) * | 2017-04-12 | 2017-12-01 | 华东师范大学 | 一种基于2,2‑二甲基‑3‑（2‑硝基咪唑基）丙酸的低氧激活前药 |
| WO2019055786A1 (en) * | 2017-09-14 | 2019-03-21 | Lankenau Institute For Medical Research | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| PE20210367A1 (es) | 2018-02-02 | 2021-02-26 | Maverix Oncology Inc | Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina |
| US11497726B2 (en) | 2018-03-16 | 2022-11-15 | Dfb Soria, Ll. | Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| KR102747229B1 (ko) | 2021-08-10 | 2024-12-31 | 경북대학교 산학협력단 | 두경부암의 예후 예측을 위한 암 관련 섬유아세포의 바이오마커 |
| JP2024531479A (ja) | 2021-08-27 | 2024-08-29 | アセンタウィッツ ファーマシューティカルズ リミテッド | 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用 |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| CN113968867A (zh) * | 2021-11-10 | 2022-01-25 | 聊城大学 | 一种喜树碱类前药及其用途 |
| US20240424011A1 (en) * | 2021-12-21 | 2024-12-26 | University Of Tsukuba | Combination therapy of hypoxia-responsive prodrug of an anticancer drug and radiotherapy, and novel hypoxia-responsive prodrug |
| CN114617876B (zh) * | 2022-01-28 | 2023-04-07 | 四川大学华西医院 | 一种抗肿瘤联合用药物 |
| CN116675620B (zh) | 2022-02-22 | 2025-01-10 | 东南大学 | No供体化合物及其制备方法、药物组合物和应用 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| US20250295677A1 (en) | 2022-04-15 | 2025-09-25 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by using th-302 alone or in combination with parp inhibitor |
| CN119233822A (zh) | 2022-05-23 | 2024-12-31 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| WO2024061346A1 (zh) | 2022-09-22 | 2024-03-28 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| TW202434258A (zh) | 2023-02-27 | 2024-09-01 | 大陸商深圳艾欣達偉醫藥科技有限公司 | 溶液、凍乾製劑、凍乾製劑單位包裝、注射液及注射液配製方法 |
| AU2024317010A1 (en) | 2023-07-28 | 2026-02-26 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652579A (en) * | 1969-06-26 | 1972-03-28 | Hoffmann La Roche | 1-methyl-2-substituted 5-nitroimidazoles |
| DE2229248C3 (de) | 1971-07-30 | 1980-03-27 | Gruppo Lepetit S.P.A., Mailand (Italien) | 5-Iminomethyl-2-nitroimidazoI-Derivate und Verfahren zu deren Herstellung |
| US4921963A (en) * | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
| JPH0819111B2 (ja) | 1987-10-22 | 1996-02-28 | ポーラ化成工業株式会社 | ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤 |
| US4908356A (en) * | 1988-05-25 | 1990-03-13 | Research Corporation Technologies, Inc. | Aldophosphamide derivatives useful as antitumor agents |
| US5403932A (en) * | 1988-05-25 | 1995-04-04 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| US5190929A (en) * | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
| DE3835772A1 (de) * | 1988-10-20 | 1990-04-26 | Deutsches Krebsforsch | Tumorhemmende saccharid-konjugate |
| KR927003539A (ko) * | 1990-01-26 | 1992-12-18 | 스즈끼 쯔네시 | 2-니트로 이미다졸 유도체, 그의 제조방법 및 이를 유효성분으로 하는 방사선 증감제 |
| US5233031A (en) * | 1991-09-23 | 1993-08-03 | University Of Rochester | Phosphoramidate analogs of 2'-deoxyuridine |
| CA2122036C (en) * | 1991-10-23 | 2002-09-17 | Gillian Anlezark | Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form |
| US5750782A (en) * | 1992-11-27 | 1998-05-12 | Cancer Research Campaign Technology Limited | Nitroaniline derivatives and their use as anti-tumour agents |
| US5306727A (en) * | 1993-04-30 | 1994-04-26 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| WO1994027954A1 (en) * | 1993-05-25 | 1994-12-08 | Auckland Uniservices Limited | Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents |
| EP0648503B1 (en) * | 1993-09-22 | 2000-07-26 | Hoechst Aktiengesellschaft | Pro-prodrugs, their production and use |
| JPH07309761A (ja) * | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| US5659061A (en) | 1995-04-20 | 1997-08-19 | Drug Innovation & Design, Inc. | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities |
| GB9516943D0 (en) | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
| GB9526391D0 (en) | 1995-12-22 | 1996-02-21 | Diversey Equipment Technologie | Dispenser |
| US6218519B1 (en) * | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
| US6130237A (en) * | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| US6251933B1 (en) * | 1996-12-13 | 2001-06-26 | The Cancer Research Campaign Technology Limited | Seco precursors of cyclopropylindolines and their use as prodrugs |
| DE19720312A1 (de) * | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| US6240925B1 (en) * | 1999-03-23 | 2001-06-05 | Cynosure, Inc. | Photothermal vascular targeting with bioreductive agents |
| GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| EP1185276B1 (en) * | 1999-05-24 | 2003-12-10 | Southern Research Institute | Isophosphoramide mustard analogs and use thereof |
| AU5935600A (en) * | 1999-07-14 | 2001-01-30 | Richard F. Borch | Phosphoramide compounds |
| US6903081B2 (en) * | 2000-03-31 | 2005-06-07 | Purdue Research Foundation | Phosphoramidates and methods therefor |
| JP2002046334A (ja) | 2000-08-04 | 2002-02-12 | Riso Kagaku Corp | 孔版印刷装置及び該装置の印刷ドラム |
| EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US6506739B1 (en) | 2001-05-01 | 2003-01-14 | Telik, Inc. | Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents |
| US7129261B2 (en) * | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| FR2825926A1 (fr) * | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
| US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| KR20030067275A (ko) | 2002-02-07 | 2003-08-14 | 주식회사 하이폭시 | 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제 |
| JP4187096B2 (ja) | 2003-01-15 | 2008-11-26 | 独立行政法人科学技術振興機構 | ３次元フォトニック結晶製造方法 |
| GB0306908D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Bioreductively activated stilbene prodrugs |
| GB0306907D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Boireductively-activated prodrugs |
| ZA200507752B (en) * | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| US6855695B2 (en) * | 2003-06-13 | 2005-02-15 | Vion Pharmaceuticals, Inc. | Water-soluble SHPs as novel alkylating agents |
| KR101226631B1 (ko) | 2004-02-06 | 2013-01-28 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 항암 치료 방법 |
| MX2007006102A (es) | 2004-11-22 | 2007-07-11 | Threshold Pharmaceuticals Inc | Agentes anti-cancer de union a tubulina y profarmacos de los mismos. |
| WO2008011588A2 (en) | 2006-07-20 | 2008-01-24 | Threshold Pharmaceuticals, Inc. | Glycoconjugates of phosphoramidate alkylators for treatment of cancer |
| WO2008076826A1 (en) | 2006-12-13 | 2008-06-26 | Threshold Pharmaceuticals, Inc. | Pyrophosphoramide alkylators |
| EP2114157B1 (en) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
-
2004
- 2004-03-28 ZA ZA200507752A patent/ZA200507752B/en unknown
- 2004-03-29 CA CA2520000A patent/CA2520000C/en not_active Expired - Lifetime
- 2004-03-29 US US10/549,545 patent/US7550496B2/en not_active Expired - Lifetime
- 2004-03-29 CN CNA2004800132768A patent/CN1791403A/zh active Pending
- 2004-03-29 EP EP13178249.2A patent/EP2671581B8/en not_active Expired - Lifetime
- 2004-03-29 CN CN2010105956028A patent/CN102161679A/zh active Pending
- 2004-03-29 AU AU2004226338A patent/AU2004226338C1/en not_active Expired
- 2004-03-29 NZ NZ543223A patent/NZ543223A/en not_active IP Right Cessation
- 2004-03-29 EP EP04749522A patent/EP1622608A4/en not_active Withdrawn
- 2004-03-29 MX MXPA05010407A patent/MXPA05010407A/es active IP Right Grant
- 2004-03-29 KR KR1020127002215A patent/KR101198526B1/ko not_active Expired - Lifetime
- 2004-03-29 JP JP2006509466A patent/JP2006521409A/ja not_active Ceased
- 2004-03-29 KR KR1020057018367A patent/KR20050113670A/ko not_active Withdrawn
- 2004-03-29 ES ES13178249T patent/ES2759176T3/es not_active Expired - Lifetime
- 2004-03-29 WO PCT/US2004/009667 patent/WO2004087075A2/en not_active Ceased
-
2005
- 2005-09-19 IL IL170970A patent/IL170970A/en active IP Right Grant
- 2005-10-26 NO NO20054988A patent/NO336266B1/no not_active IP Right Cessation
-
2009
- 2009-06-12 US US12/484,104 patent/US8299088B2/en not_active Expired - Fee Related
-
2012
- 2012-01-26 JP JP2012014178A patent/JP5572644B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012082227A5 (https=) | ||
| JP7179357B2 (ja) | ２－アミノ－キノリン誘導体 | |
| RU2697707C9 (ru) | Процессы приготовления производных соединений дигидропиримидина и их промежуточных продуктов | |
| TWI607007B (zh) | ４－胺基－咪唑并喹啉化合物 | |
| JP2010501572A5 (https=) | ||
| EP2367809B1 (en) | Derivatives of [(3-hydroxy-4 pyron-2-yl)methyl]-amine and use thereof as anti-neoplastic drugs | |
| EP3325485B1 (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| JP2016512823A5 (https=) | ||
| JP2010513494A5 (https=) | ||
| JP2013503846A5 (https=) | ||
| JP2012504628A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| CN105121439A (zh) | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 | |
| JP2022166016A (ja) | ソマトスタチンモジュレーターを製造するプロセス | |
| US20110178041A1 (en) | Heterocyclic biaryl derivative and pde inhibitor comprising same as active ingredient | |
| WO2018154104A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| KR20180128937A (ko) | 질환을 치료하는데 유용한 fimh의 만노스-유래 길항제 | |
| HRP20221067T1 (hr) | Postupak priprave 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiona i njegovih soli | |
| JP2019504833A5 (https=) | ||
| JP2009503110A5 (https=) | ||
| CN109081828B (zh) | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 | |
| RU2008128568A (ru) | (1-азабицикло[3,3,1]нон-4-ил)-[н-индол-5-ил)-гетероарил]-амины, как холинергические лиганды n-achr, предназначенные для лечения психотических и нейродегенеративных нарушений | |
| CN105566260B (zh) | 一种呋塞米的制备方法 | |
| RU2015101702A (ru) | Фармацевтически активные соединения | |
| JP2012503653A5 (https=) |